Tiantan Bio
600161.SSPhase 2Tiantan Bio is a major player in China's biopharmaceutical sector, with a core focus on plasma-derived therapeutics and vaccines. As part of the Sinopharm Group ecosystem, it benefits from significant scale and strategic importance in public health. The company leverages its extensive plasma collection network and manufacturing capabilities to serve the large domestic market, with a pipeline that includes both biosimilars and novel biological products.
600161.SS · Stock Price
Historical price data
AI Company Overview
Tiantan Bio is a major player in China's biopharmaceutical sector, with a core focus on plasma-derived therapeutics and vaccines. As part of the Sinopharm Group ecosystem, it benefits from significant scale and strategic importance in public health. The company leverages its extensive plasma collection network and manufacturing capabilities to serve the large domestic market, with a pipeline that includes both biosimilars and novel biological products.
Technology Platform
Large-scale plasma fractionation and purification platform for producing albumin, immunoglobulins, and coagulation factors, combined with traditional and modern vaccine development technologies.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Endostatin | Vestibular Schwannoma | Phase 2 | |
| CN-105 | Intracerebral Hemorrhage | Phase 2 | |
| human allogeneic induced pluripotent stem cell (iPSC)-derive... | Parkinson's Disease | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Tiantan Bio's main competitors are domestic firms like China Biologic Products, Shanghai RAAS, and Hualan Biological in plasma products, and Walvax and CanSino in vaccines. Its primary differentiation is its state-backed scale, integrated supply chain from plasma to product, and strategic role in China's national public health infrastructure.